| Literature DB >> 26097763 |
H T El-Bassyouni1, H H Afifi1, M M Eid2, R M Kamal3, H H El-Gebali3, Gsm El-Saeed4, M M Thomas1, S A Abdel-Maksoud5.
Abstract
BACKGROUND: Oxidative stress plays a major role in the pathogenesis of leukemia-prone diseases such as Fanconi anemia (FA) and Down syndrome (DS). AIM: To explore the oxidative stress state in children with DS and FA by estimating the levels of antioxidants (e.g., malondialdehyde [MDA], total antioxidant capacity, and superoxide dismutase [SOD] activity) and DNA damage, and to evaluate of the effect of antioxidant treatment on these patients. SUBJECTS AND METHODS: The study included 32 children clinically diagnosed with (15 patients) and FA (17 patients) in addition to 17 controls matched for age and sex. MDA, total antioxidant capacity, SOD activity, and DNA damage were measured. Antioxidants including Vitamin A, E, and C were given to the patients according to the recommended daily allowance for 6 months. Clinical follow-up and re-evaluation were conducted for all patients. Laboratory tests including complete blood count, karyotyping, DNA damage, and oxidative stress were re-evaluated. Statistical analysis was performed using statistical computer program Statistical Package for the Social Sciences version 14.0.Entities:
Keywords: Down syndrome; Oxidative DNA damage; Oxidative stress
Year: 2015 PMID: 26097763 PMCID: PMC4455011 DOI: 10.4103/2141-9248.157511
Source DB: PubMed Journal: Ann Med Health Sci Res ISSN: 2141-9248
Clinical data of group I (Fanconi anemia)
Comparison of the clinical manifestations before and after antioxidants intake in the group I (FA)
Figure 1Comparison between malondialdehyde, total antioxidant capacity, and superoxide dismutase mean levels before and after antioxidants therapy in Fanconi anemia patients compared to controls
Figure 2Comparison between diepoxybutane and DNA damage before and after antioxidants therapy in the group I (Fanconi anemia)
Figure 4High power image of comet assay showing, (a) extensive DNA damage. (b) Less DNA damage after treatment
Figure 5Comparison between malondialdehyde, total antioxidant capacity, and superoxide dismutase mean levels before and after antioxidants therapy between group II and controls
Comparison between the clinical manifestations before and after antioxidants intake in group II (down syndrome)
Figure 6Comparison between DNA damage levels before and after antioxidants therapy in group II and controls
Figure 7Differences of oxidative stress parameters in the group I and II before and after taking antioxidants compared with the controls
Figure 8Differences of DNA damage in the group I and II before and after taking antioxidants compared with the controls